Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator

Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
American Association of Individual Investors

Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 5.64%

As of Friday, January 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 5.64%, which has investors questioning if ...
American Association of Individual Investors

Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 5.26%

As of Friday, January 23, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 5.26%, which has investors ...
Clinical Trials Arena on MSN

ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study

As of 22 January, 19 of the 23 patients who have received treatment are still alive, with the longest evaluable survival ...
The American Journal of Managed Care

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
News Medical on MSN

MYC cancer gene suppresses immune alarm signals to protect pancreatic tumors

The cancer gene MYC camouflages tumors by suppressing alarm signals that normally activate the immune system. This finding from a new study offers a promising way to improve existing cancer therapies ...